Use of Insulin Glargine to Treat Diabetic Ketoacidosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00179127
Recruitment Status : Unknown
Verified June 2012 by Sheila McMorrow, Vanderbilt University.
Recruitment status was:  Active, not recruiting
First Posted : September 15, 2005
Last Update Posted : June 21, 2012
Information provided by (Responsible Party):
Sheila McMorrow, Vanderbilt University

Brief Summary:

The purpose of this study is to determine the effects of the addition of insulin glargine during the early phase of moderate to severe Diabetic Ketoacidosis (DKA) in children.

The investigators hypothesize that the addition of insulin glargine during the early phase of management of DKA will accelerate acidosis correction, decrease the length of insulin infusion, and decrease the total intensive care unit time in children admitted to the ICU.

Condition or disease Intervention/treatment Phase
Diabetic Ketoacidosis Drug: glargine Drug: saline Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 75 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Early Use of Insulin Glargine in Diabetic Ketoacidosis
Study Start Date : August 2004
Actual Primary Completion Date : July 2009
Estimated Study Completion Date : September 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: A Drug: glargine
0.3u/kg of glargine, subq, once

Placebo Comparator: B Drug: saline
0.3cc/kg of saline, subq, once

Primary Outcome Measures :
  1. Time of acidosis correction [ Time Frame: Minutes ]

Secondary Outcome Measures :
  1. Time on insulin drip [ Time Frame: Minutes ]
  2. Total hospital stay [ Time Frame: Days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   6 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Ages 6-18 y.o. presenting to VCH E.R. with:
  • Established history of insulin dependent diabetes


  • Chief c/o hyperglycemia or vomiting
  • Venous pH < 7.24
  • Serum Bicarbonate < 18
  • Blood glucose > 150
  • Urinary Ketones

Exclusion Criteria:

  • Age < 6y.o.
  • New onset diabetes
  • Received IV insulin bolus prior to arrival to VCH E.R.
  • Venous pH > 7.24
  • Serum Bicarbonate > 18
  • Pregnancy
  • Received glargine within 12 hours prior to arrival to VCH E.R./PCCU

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00179127

United States, Tennessee
Vanderbilt University Monroe Carell Children's Hospital
Nashville, Tennessee, United States, 37232
Sponsors and Collaborators
Vanderbilt University
Principal Investigator: Sheila McMorrow, MD Vanderbilt University

Responsible Party: Sheila McMorrow, Assistant Professor, Vanderbilt University Identifier: NCT00179127     History of Changes
Other Study ID Numbers: 040643
First Posted: September 15, 2005    Key Record Dates
Last Update Posted: June 21, 2012
Last Verified: June 2012

Keywords provided by Sheila McMorrow, Vanderbilt University:
Emergency Care
Critical Care

Additional relevant MeSH terms:
Diabetic Ketoacidosis
Acid-Base Imbalance
Metabolic Diseases
Diabetes Mellitus
Glucose Metabolism Disorders
Diabetes Complications
Endocrine System Diseases
Insulin Glargine
Hypoglycemic Agents
Physiological Effects of Drugs